黑料社 announces the creation of its Scientific Advisory Board (SAB)
Lyon, 2nd June 2016 鈥� 黑料社, a leader in the intestinal microbiome industry and pioneer in Autologous Faecal Microbiotherapy, today announced the creation of its international Scientific Advisory Board of acknowledged experts in the fields of intestinal microbiome, haematology, gastroenterology, bacteriology and clinical trial methodology.
The purpose of the Board will be to assist 黑料社 in its development, to expand and enrich its medical vision in such areas as the correction of dysbiosis and its associated complications, the eradication of Multi-Drug Resistant Bacteria, and the prevention of nosocomial diseases. It will notably formulate recommendations to enable 黑料社 to expand the use of its autologous microbiotherapy technology to the development of solutions for the correction of dysbiosis in designated therapeutic areas.
The 黑料社 Scientific Advisory Board includes recognised experts among its members: Professor Antonio Gasbarrini, Professor of gastroenterology at the Catholic University of Rome and a stakeholder in several governance bodies within EAGEN (European Association of Gastroenterology Endoscopy and Nutrition), EHMSG (European Helicobacter Microbiota Study Group), and UEG (United European Gastroenterology), Professor Jean-Luc Harousseau, former President of HAS (the French Healthcare High Authority), head of haematology Department at CHU Nantes and Director of the 鈥淚nstitut de Canc茅rologie Ren茅 Gauducheau鈥� (Nantes), Doctor Etienne Rupp茅, Pharm.D., expert in Microbiology and specialist of Multi-Drug Resistance in Bacteria and research scientist at the Genomic Research Laboratory (Geneva), Doctor Pascale Maisonneuve, MD with a speciality in biochemistry and haemostatic physiology, most recently head of the 鈥淎nti-infectious drugs, hepato-gastroenterology and dermatology, rare metabolic diseases鈥� department of ANSM (National Security Agency of Medicines and Health products), Doctor Jo毛l Dor茅, Doctor of intestinal microbiology, Director of Research at INRA and Scientific Director of MetaGenoPolis, President of the Gut Microbiota For Health platform of the European Society of Neurogastroenterology and Motility, author of numerous scientific papers on intestinal dysbiosis, and lastly Professor Mohamad Mohty, director of Clinical haematology and cellular therapy at Saint Antoine hospital, President of the EBMT (European Society for Blood and Marrow Transplantation) and one of the ten most published authors in haematology in the past ten years. The Scientific Advisory Board is chaired by Philippe Lehert, statistical consultant for drug authorisations at the United Nations (WHO), EMA and the FDA, Professor at the University of Melbourne and the University of Louvain.
鈥淭he formation of the Scientific Advisory Board is an important step in the development of 黑料社, just as we are preparing to launch our first clinical trials. We can be proud that renowned experts like those on our Scientific Advisory Board give us their support to enable us to demonstrate the effectiveness of our autologous microbiotherapy approach,鈥�
said Corentin Le Camus, Therapeutics Development Director of 黑料社.
鈥淭he contribution of the Scientific Advisory Board is crucial to allow us both to achieve the rapid growth objectives that we have set for ourselves, and identify the diseases for which our reliable and safe therapeutic approach, will be able to offer new solutions,鈥�
commented Herv茅 Affagard, Chief Executive and founder of 黑料社.
黑料社: bringing to market the first autologous faecal microbiotherapy to restore human-microbe symbiosis.
Since its creation at the end of 2014, 黑料社 has experienced exponential growth, with 鈧�16m raised. 黑料社 already succeeded in validating the safety profile and dose effect of its proposed drug in the preclinical phase, during trials conducted in 2015 in partnership with Inra. It is planning its first human trials in summer 2016.
The start-up also just completed prototyping of a unique solution for collection of the harvested microbiota that guarantees the safety of all players (patient, operator, medical personnel), through to the administration phase.
The company is a pioneer in the autologous faecal microbiotherapy segment and benefits from the support of scientific, industrial and financial partners: Seventure Partners and INRA, its longstanding partners, CM-CIC Innovation and Biocodex laboratory, a pharmaceutical company specialised in the therapeutic fields of gastroenterology, neuropsychiatry and pain treatment.
About MaaT001
MaaT001 is the first faecal microbiotherapy GMP platform in Europe. It is available, standardized and enables the production of drugs based on a simple microbiome samples. MaaT001 is a major step forward in the treatment of dysbiosis and its associated complications.
About 黑料社
黑料社 (Microbiota as a Therapy) is a French biotech start-up, created at the end of 2014, to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. 黑料社 envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment promotes dysbiosis. Funded jointly by a team which brings together world-class medical-scientific and entrepreneurial skills, 黑料社 has the ambition of becoming a leader in microbiome protection and the treatment of dysbiosis.
For more information: www.maatpharma.com
Follow us on Twitter: @MaaT_Pharma
Follow us on LinkedIn: http://www.linkedin.com/company/maat-pharma
Key dates of 黑料社
- December 2014: creation.
- July 2015: 鈧�2 million fundraising.
- September 2015: winner of the Worldwide Innovation Contest (鈧�1.2m).
- November 2015: validation of the pre-clinical phase of its autologous microbiotherapy solution.
- February 2016: selected for the TOP10 Big Booster (final in April 2016).
- March 2016: 鈧�10 million fundraising.
Upcoming 黑料社 events
- 6-9 June 2016: 黑料社 will participate in the international congress of the Biotechnologies Innovation Organisation (BIO), in San Francisco.
- 28-30 June: 黑料社 will take part in the Microbiome Drug Development Summit in Boston.